DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

8-K - SQZ Biotechnologies Co (0001604477) (Filer)

EFFECT - SQZ Biotechnologies Co (0001604477) (Filer)

POS AM - SQZ Biotechnologies Co (0001604477) (Filer)

S-8 POS - SQZ Biotechnologies Co (0001604477) (Filer)

10-Q - SQZ Biotechnologies Co (0001604477) (Filer)

8-K - SQZ Biotechnologies Co (0001604477) (Filer)

8-K - SQZ Biotechnologies Co (0001604477) (Filer)

Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

Strategically Focused Company Structure to Prioritize Clinical Development and Deliver Critical, Clinical-Stage Data SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 Phase 1 SQZ-AAC-HPV-101 Clinical Trial to Continue Following the Recent Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates. "The team is focused on our key initiatives

SQZ Biotechnologies (NYSE:SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company's common stock from the NYSE. The Company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE's continued listing standards. Under NYSE rules, the Company has a period of six months from receipt of the NYSE

Designation Represents Potential to Bring Important New Therapy to Patients Earlier Stable Disease Observed in Two Out of Four Evaluable Patients in eAPC Phase 1/2 Trial Including a Pronounced Pharmacodynamic Response in a Patient with Prolonged Stable Disease Interim Results from Ongoing SQZ® eAPC Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated Median Drug Viability of Greater than 90 Percent for Both SQZ® eAPC and SQZ® APC Clinical Trials SQZ Biotechnologies Company (NYSE:SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's Enhanced Antigen Presenting Cell (

Strategic Reprioritization of Portfolio: Focus on Advancing Second-Generation Cell Therapy Program, Enhanced Antigen Presenting Cells Howard Bernstein, MD, PhD, Former Chief Scientific Officer, Appointed as Interim Chief Executive Office; Armon Sharei, PhD, to step down from role as CEO and member of the Board of Directors Company to Reduce Workforce by Approximately 60%; Initial Cost Saving Measures Expected to Extend Cash Runway Into 2024 SQZ Biotechnologies (NYSE:SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program, focused on HPV16 positive r

Cell Squeeze® Platform Offers Advantages for GMP Engineering of Multiple Cell Types and Reduced Manufacturing Time and Cost through its Point-of-Care System mRNA Constructs Encoding Multiple Linked Antigens Could Allow for a Multiantigen-Specific CD8+ T Cell Response SQZ® eAPCs Contain Five mRNAs Encoding for Proteins Stimulating the Key T Cell Activation Signals to Potentially Mount Potent Immune Response Against Tumors SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, will present preclinical research demonstrating the potential of its Cell Squeeze® technology to multiplex engineer a diverse set of cell types, incl

Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in Immunology Continued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company's Point-of-Care System Anticipate Interim Clinical Data for HPV16+ Solid Tumors by the End of 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates. "I am proud of the SQZ team's accomplishments this quarter, including our publication showcasing the AAC platf

Activating Antigen Carriers (AACs) Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor Killing Demonstrated Improved Efficacy of AAC Therapy Through Combination with Chemotherapy Agent SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ® Activating Antigen Carrier (AAC) platform. The data, published in Frontiers in Immunology, demonstrated that the company's Cell Squeeze® platform can be used to generate AACs by engineering red blood cells (RBCs) with antigen and adjuvant that can drive antigen-specific